MobbleOpen in Mobble ⇢
Business · Stock markets · published 2026-10-10 · via StockTitan

MannKind Shares Data Backing Furoscix ReadyFlow for Outpatient Fluid Overload

Image via StockTitan
Image via StockTitan

MannKind announced new analyses of Furoscix ReadyFlow showing comparable urine output to intravenous furosemide for outpatient fluid overload. A randomized crossover study found equivalent total drug exposure at thigh and upper-arm injection sites, with relative bioavailability of 91.3% and 92.7%. The findings were scheduled for presentation at HFSA 2026, and ReadyFlow received FDA approval in July 2026.

Read the full article at StockTitan →
Also covered by: BiopharmaWatch
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | MNKD Stock News.” Browse more stories.